Abbott Willfully Infringed On Innogenetics’ Hepatitis C Patent, Jury Finds
This article was originally published in The Gray Sheet
Innogenetics is seeking an injunction against Abbott's hepatitis C genotyping reagents after a $7 mil. jury verdict in its favor
You may also be interested in...
Azar says ACIP’s prioritization recommendations should carry weight, but states will be final arbiter of who is vaccinated.
Sanofi R&D head John Reed says the company has kept 95% of patients on its nearly 400 clinical trials, started 59 studies, and benefited from its in-house drug supply management.
The funding will be used to support clinical and preclinical development at its portfolio companies, with 8-10 programs in the clinic in 2021.